Previous 10 | Next 10 |
home / stock / lbtsf / lbtsf news
Almirall, S.A. (LBTSF) Q2 2021 Earnings Conference Call July 26, 2021 4:00 AM ET Company Participants Pablo Divasson – Head of Investor Relations Gianfranco Nazzi – Chief Executive Officer Karl Ziegelbauer – Chief Scientific Officer Mike McClellan – Chief Financial...
The following slide deck was published by Almirall, S.A. in conjunction with their 2021 Q2 earnings call. For further details see: Almirall, S.A. 2021 Q2 - Results - Earnings Call Presentation
Almirall, S.A. (LBTSF): 1H Normalised net income of €57.8MRevenue of €415.5M (-4.0% Y/Y) misses by $81.18M.The company is upgrading its Core EBITDA Guidance for 2021 to €195 MM - €215M (previously €190 MM-€210M)Press Release For further details see:...
Almirall delivers robust H1 performance and increases full-year guidance - Robust business performance with significant growth in Core EBITDA: Core Net Sales €415.5 MM (+8% year-on-year) and Core EBITDA reached €125.6 MM, (+40.4% year-on-year) - The company is ...
Almirall receives European Commission approval of Klisyri® (tirbanibulin), an innovative topical treatment for actinic keratosis - Klisyri® (tirbanibulin) is a topical first-in-class microtubule inhibitor indicated for the treatment of actinic keratosis (AK) of the fac...
Almirall receives positive CHMP opinion for Klisyri®▼ (tirbanibulin), an innovative topical treatment for actinic keratosis Klisyri® (tirbanibulin) is a novel microtubule inhibitor, indicated for the topical treatment of actinic keratosis (AK) of the face or sca...
The following slide deck was published by Almirall, S.A. in conjunction with their 2021 Q1 earnings call. For further details see: Almirall, S.A. 2021 Q1 - Results - Earnings Call Presentation
Almirall SA. (LBTSF) Q1 2021 Earnings Conference Call May 10, 2021, 04:00 AM ET Company Participants Pablo Divasson - Head, IR & CEC Jorge Ballart - Chairman, PD Carlos Gallardo - VC & PD Gianfranco Nazzi - CEO Michael McClellan - EVP, Finance & CFO Conference Call Participants Ja...
Almirall's solid core business Q1 performance boosted by Growth drivers momentum - Good business performance with significant growth in Core EBITDA: Core Net Sales €215.4 MM (+5% year-on-year) and Core EBITDA €68.0MM (+46% year-on-year) - Growth drivers momentu...
Almirall, S.A. (LBTSF): FY normalized Net Income of €95.1MRevenue of €814.5M (-10.3% Y/Y)Press Release For further details see: Almirall, S.A. reports FY results
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Strong growth trajectory maintained with Net Sales increase of 6.7% to a total of €497.2 MM, EBITDA of €104.5 MM (+3.2% YoY) driven by increased overall sales and strong performance of biologics portfolio Biologics continue to be key growth engines for Almirall: Ebglyss ...
Lebrikizumab is recommended by NICE for the use in moderate to severe Atopic Dermatitis in patients 12 years and over when their condition has not responded to at least 1 systemic immunosuppressant, or when these treatments are not suitable Following approval of the European Commission (Octob...
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...